

Palivizumab prophylaxis – AAP Guidelines

<u>New Guidelines</u>	<u>Old Guidelines</u>
In the 1 st year of life for infants born < 29 wks GA*	Recommended for infants born < 32 wks GA AND Infants 32-34 6/7 wks GA with risk factors
In the 1 st year of life for infants < 32 wks GA with chronic lung disease (CLD) <i>(CLD defined as > 21% oxygen ≥ 28 days after birth)</i>	CLD not specifically defined.
May administer in the first year of life to infants with hemodynamically significant heart disease. <i>(Infants with cyanotic cardiac disease should have consultation with a cardiologist for prophylaxis recommendations.)</i>	Prophylaxis recommended in the 1 st and 2 nd year of life for infants with hemodynamically significant heart disease.
May administer up to a maximum of 5 monthly doses during the RSV season in the first year of life. Qualifying infants born during the RSV season will require fewer doses. For example, infants born in January would receive their last dose in March.	Fewer than five doses were recommended for some infants.
Prophylaxis recommended in the 2 nd year of life ONLY for those who require ≥ 28 days of supplemental oxygen after birth and who continue to require medical intervention (supplemental oxygen, chronic steroids, diuretics).	Two years of prophylaxis was recommended for qualifying infants.
Monthly prophylaxis should be DISCONTINUED in any child who experiences a breakthrough of RSV hospitalization.	Continuation of prophylaxis was recommended with a breakthrough RSV hospitalization.
Children with pulmonary abnormality or neuromuscular disease that impairs the ability to clear secretions from the lower airways MAY BE CONSIDERED for prophylaxis in the 1 st year of life.	Two years of prophylaxis was recommended for qualifying infants.
Children less than 24 months who will be profoundly immunocompromised during the RSV season MAY BE CONSIDERED for prophylaxis.	No change.
No prophylaxis recommended (due to insufficient data) for children with cystic fibrosis or Down syndrome.	Recommendation for cystic fibrosis was similar. Down syndrome was not addressed.
Prophylaxis not recommended for prevention of RSV nosocomial disease.	No change.

*GA in table = gestational age

References:

AAP News 2014;35;1.

AAP Policy Statement. *Pediatrics* 2014;134:415-20.

AAP Technical Report. *Pediatrics* 2014;134:e620-38.

Prepared: 9/4/14

By: Paige Fuller, PharmD, BCPS & Amy Potts, PharmD, BCPS